6-bromo-3,4-diethoxybenzaldehyde dimethyl acetal | 155044-03-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6-bromo-3,4-diethoxybenzaldehyde dimethyl acetal
• 英文别名: 1-Bromo-2-(dimethoxymethyl)-4,5-diethoxybenzene
• CAS: 155044-03-4
• 化学式: C₁₃H₁₉BrO₄
• 分子量: 319.195
• InChiKey: SMGCJDIGXINQPR-UHFFFAOYSA-N

物化性质

• 沸点：
  338.0±42.0 °C(Predicted)
• 密度：
  1.279±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  36.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-bromo-3,4-diethoxybenzaldehyde dimethyl acetal 在 盐酸 、 sodium hydroxide 、 sodium chlorite 、 正丁基锂 、 acetate buffer 、 potassium carbonate 、 间苯二酚 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 水 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 8.75h， 生成 6,7-Diethoxy-3-hydroxy-1-oxo-4-(3,4,5-trimethoxy-phenyl)-isochroman-3-carboxylic acid
  参考文献：
  名称：

  Novel, Potent, and Selective Phosphodiesterase 5 Inhibitors:  Synthesis and Biological Activities of a Series of 4-Aryl-1-isoquinolinone Derivatives

  摘要：

  A novel class of potent and selective phosphodiesterase 5 (PDE5) inhibitors, 4-aryl-1-iso-quinolinone derivatives, which have been designed by the comparison of the structure of cGMP and a previously reported 1-arylnaphthalene lignan, was disclosed. Among these compounds, methyl 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)- 3-isoquinoline carboxylate dihydrochloride (36a) exhibited potent PDE5 inhibitory activity (IC50 = 1.0 nM) with high isozyme selectivities (IC50 ratio: PDE1/PDE5 = 1300, PDE2/PDE5 > 10 000, PDE3/PDE5 > 10 000, PDE4/PDE5 = 4700, PDE6/PDE5 = 28). Compound 36a also showed the most potent relaxant effect on isolated rabbit corpus cavernosum (EC30 = 7.9 nM). Compound 63 (T-1032), the sulfate form of 36a, was selected for further biological and pharmacological evaluation of erectile dysfunction.

  DOI：

  10.1021/jm000558h

文献信息

• A synthesis of 1-pyridylnaphthalene lignan analogs
  作者：Masakatsu Sugahara、Yasunori Moritani、Yoshihiro Terakawa、Tsuyoshi Ogiku、Tatsuzo Ukita、Tameo Iwasaki

  DOI：10.1016/s0040-4039(97)10849-8

  日期：1998.3

  A new series of 1-arylnaphthalene lignan analogs having a variety of pyridyl substituents at the C-1 position were synthesized in moderate to good yields by means of the Diels-Alder reaction by utilizing 1-pyridylisobenzofuran precursors with dimethyl fumarate, methyl acrylate, or dimethyl acetylene dicarboxylate, followed by BF3·Et2O-mediated aromatization.

  利用Diels-Alder反应，利用1-吡啶基异苯并呋喃前体与富马酸二甲酯，丙烯酸甲酯或乙炔二甲酸二甲酯，然后由BF 3 ·Et 2 O介导的芳构化。
• Pharmaceutical pyridine derivatives, processes for preparing the same and intermediates therefor
  申请人：TANABE SEIYAKU CO., LTD.

  公开号：EP0848000A1

  公开（公告）日：1998-06-17

  A pyridine derivative of the formula (I): wherein A is group of the following formulae: R1 and R2 are each H, or protected or unprotected OH, R31, R41 and R42 are protected or unprotected hydroxymethyl, R32 is H, lower alkyl, or protected or unprotected hydroxymethyl, R33 is substituted or unsubstituted lower alkyl, and the dotted line means the presence or absence of a double bond' R5 and R6 are H, or protected or unprotected amino, or both combine together with the adjacent nitrogen to form substituted or unsubstituted heterocycle, or a pharmaceutically acceptable salt thereof, show excellent bronchoconstriction inhibitory activity and/or anti-inflammatory activity of airways, and are , useful in the prophylaxis or treatment of asthma.

  式（I）的吡啶衍生物： 其中 A 为下式中的基团： R1 和 R2 分别为 H，或受保护或未受保护的 OH，R31、R41 和 R42 为受保护或未受保护的羟甲基，R32 为 H、低级烷基或受保护或未受保护的羟甲基，R33 为取代或未取代的低级烷基，虚线表示存在或不存在双键' R5 和 R6 为 H、或受保护或未受保护的氨基，或两者与相邻的氮结合在一起形成取代或未取代的杂环，或其药学上可接受的盐，显示出优异的支气管收缩抑制活性和/或气道抗炎活性，可用于预防或治疗哮喘。
• Novel, Potent, and Selective Phosphodiesterase-4 Inhibitors as Antiasthmatic Agents:  Synthesis and Biological Activities of a Series of 1-Pyridylnaphthalene Derivatives
  作者：Tatsuzo Ukita、Masakatsu Sugahara、Yoshihiro Terakawa、Tooru Kuroda、Kazuteru Wada、Aya Nakata、Yasushi Ohmachi、Hideo Kikkawa、Katsuo Ikezawa、Kazuaki Naito

  DOI：10.1021/jm980314l

  日期：1999.3.1

  The structural requirements for potent and selective PDE4 inhibition were revealed in a 1-pyridylnaphthalene series, and the best compound (3kg, T-2585 . HCl) was chosen for further biological evaluation (PDE4 inhibition IC50 = 0.13 nM, selectivity PDE3/4 ratio = 14 000). Compound 3kg showed potent antispasmogenic activities (ED50 = 0.063 mg/kg for reduction of antigen-induced bronchoconstriction, intravenously; ED50 = 0.033 mg/kg for reduction of histamine-induced bronchoconstriction, intraduodenally) in guinea pigs with little cardiovascular effects. Furthermore, 3kg induced significantly weaker emetic effects than RP73401 after oral administration in ferrets and intravenous administration in dogs (3kg, none of 4 ferrets vomited at a dose of 10 mg/kg, po and none of 8 dogs vomited at; a dose of 0.3 mg/kg, iv; RP73401, 4 of 8 ferrets vomited at a dose of 3 mg/kg, po and 6 of 8 dogs vomited at a dose of 0.3 mg/kg, iv); that is compatible with the lower affinity for the high-affinity rolipram binding site (3kg, 2.6 nM; RP73401, 0.85 nM). This may imply that 3kg has an improved therapeutic ratio because of a broad margin between the K-i value of binding affinity and the IC50 value of PDE4 inhibition (ratio = 0.050).
• Naphthalene derivatives, process for the preparation thereof, and intermediates therefor, and pharmaceutical compositions comprising them
  申请人：TANABE SEIYAKU CO., LTD.

  公开号：EP0748805B1

  公开（公告）日：1998-04-08
• US5965730A
  申请人：——

  公开号：US5965730A

  公开（公告）日：1999-10-12